[1]杨丽娴.槐耳颗粒联合艾立布林治疗晚期三阴性乳腺癌的真实世界研究[J].医学信息,2023,36(19):144-147.[doi:10.3969/j.issn.1006-1959.2023.19.032]
　YANG Li-xian.A Real-world Study of Huai’er Granules Combined with Eribulin in the Treatment of Advanced Triple-negative Breast Cancer[J].Journal of Medical Information,2023,36(19):144-147.[doi:10.3969/j.issn.1006-1959.2023.19.032]
点击复制

槐耳颗粒联合艾立布林治疗晚期三阴性乳腺癌的真实世界研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
144-147
栏目:
药物与临床
出版日期:
2023-10-01

文章信息/Info

Title:
A Real-world Study of Huai’er Granules Combined with Eribulin in the Treatment of Advanced Triple-negative Breast Cancer
文章编号:
1006-1959（2023）19-0144-04
作者:
杨丽娴
（邢台市人民医院乳腺外科，河北 邢台 054000）
Author(s):
YANG Li-xian
(Department of Breast Surgery,Xingtai People’s Hospital,Xingtai 054000,Hebei,China)
关键词:
槐耳颗粒; 艾立布林; 乳腺癌; 肿瘤标志物; 不良反应
Keywords:
Huai’er granule; Eribulin; Breast cancer; Tumor markers; Adverse effects
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2023.19.032
文献标志码:
A
摘要:
目的 探讨槐耳颗粒和艾立布林对晚期三阴性乳腺癌的临床效果。方法 选取2019年10月-2021年11月在我院治疗的60例晚期三阴性乳腺癌为研究对象，应用随机数字表法分为治疗组和对照组，每组30例。对照组给予艾立布林治疗，治疗组在对照组基础上给予槐耳颗粒。比较两组临床疗效、卡氏评分（KPS）、生存质量评分、肿瘤标志物水平及不良反应。结果 治疗组客观改善率（ORR）、发病控制率（CBR）分别为60.00%、73.33%，高于对照组的43.33%、53.33%，差异有统计学意义（P＜0.05）；两组治疗后KPS评分及生命质量评分均有提高，同时两组血清CEA、CA125、CA153水平均有下降，且治疗组低于对照组，差异有统计学意义（P＜0.05）；治疗组化疗相关不良反应低于对照组，差异有统计学意义（P＜0.05）。结论 晚期三阴性乳腺癌患者接受槐耳颗粒与艾立布林联合治疗疗效确切，不良反应可控，安全有效。
Abstract:
Objective To study the clinical effect of Huai’er granule and eribulin in the treatment of advanced triple-negative breast cancer.Methods Sixty patients with advanced triple-negative breast cancer treated in our hospital from October 2019 to November 2021 were selected as the research objects. They were divided into treatment group and control group by random number table method, with 30 patients in each group. The control group was given elibrin, and the treatment group was given Huai’er granules on the basis of the control group. The clinical efficacy, KPS score, quality of life score, tumor marker level and adverse reactions were compared between the two groups.Results The objective response rate (ORR) and incidence control rate (CBR) in the treatment group were 60.00% and 73.33%, respectively, which were higher than 43.33% and 53.33% in the control group, and the differences were statistically significant (P<0.05). The KPS score and quality of life score of the two groups were improved after the corresponding treatment. At the same time, the serum CEA, CA125 and CA153 levels of the two groups were decreased, and those in the treatment group were lower than those in the control group, the difference was statistically significant (P<0.05). The chemotherapy-related adverse reactions in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05).Conclusion Huai’er granule combined with elibrin in the treatment of patients with advanced triple negative breast cancer is effective, the adverse reactions are controllable, safe and effective.

参考文献/References:

[1]Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics, 2021[J].CA Cancer J Clin,2021,71(1):7-33.[2]Liang Y,Zhang H,Song X,et al.Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets[J].Semin Cancer Biol,2020,60:14-27.[3]秦朝,李江,郑亚迪,等.中国城市乳腺癌高危人群筛查依从性及其相关因素分析[J].实用肿瘤学杂志,2021,35(4):291-296.[4]洪进,陈小松,吴佳毅,等.三阴性乳腺癌辅助化疗决策的影响因素分析[J].中华肿瘤杂志,2017,39(1):39-43.[5]李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015-1018.[6]Fang H,Li M,Liu Q,et al.Ultra-sensitive Nanoprobe Modified with Tumor Cell Membrane for UCL/MRI/PET Multimodality Precise Imaging of Triple-Negative Breast Cancer[J].Nanomicro Lett,2020,12(5):14.[7]Lin YJ,Kuo CN,Ko Y,et al.Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan[J].Breast,2021,57(1):18-24.[8]张建国,李洋,王冰,等.槐耳颗粒在三阴乳腺癌术后辅助治疗中的临床应用[J].牡丹江医学院学报,2014,35(5):62-63.[9]黄凯,陈夏.三阴性乳腺癌的临床病理特征和预后影响因素分析[J].中国普通外科杂志,2014,23(11):1578-1580.[10]Funahashi Y,Okamoto K,Adachi Y,et al.Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models[J].Cancer Sci,2014,105(10):1334-1342.[11]O’Shaughnessy J,Kaklamani V,Kalinsky K.Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer[J].Future Oncol,2019,15(14):1641-1653.[12]Liu Y,Zhang T,Gao Y,et al.A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practi[J].Chinese Journal of Lung Cancer,2019,22(11):687-695.[13]江泽飞,李健斌.乳腺癌诊疗指南和临床实践历程[J].中华外科杂志,2020,58(2):85-90.[14]中国抗癌协会国际医疗与交流分会,中国医师协会肿瘤医师分会乳腺癌学组.晚期乳腺癌基因检测热点问题中国专家共识(2021版)[J].中华肿瘤杂志,2022,44(1):60-67.[15]Ortega V,Lao J,Garau I,et al.MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2 [-] metastatic breast cancer (MBC) patients (pts)[J].Annals of Oncology,2016,27(supplement 6):vi68-vi99.[16]雷姗姗,王映,顾晓文,等.槐耳颗粒在三阴性乳腺癌术后辅助治疗的临床研究[J].中国普通外科杂志,2016,25(5):717-723.[17]夏念信,邱宝安,王敬晗,等.化疗联合槐耳颗粒对原发性肝癌术后复发/转移患者预后影响研究[J].临床军医杂志,2017,45(9):887-890.[18]张朦,张翠英,陈速研.槐耳颗粒联合化疗对晚期三阴性乳腺癌的抑制及肿瘤血管生成的影响[J].内蒙古医学杂志,2020,52(10):1169-1171.[19]张洪梅,史晓飒,马维维,等.槐耳增强免疫作用机制研究及其临床应用[J].辽宁中医药大学学报,2017,19(7):216-220..[20]李明,王涛.槐耳颗粒联合培美曲塞二钠和顺铂治疗乳腺癌效果分析[J].临床医药实践,2022,31(8):586-588,598.[21]王伟,史立波,张曼丽,等.乳腺癌术后化疗联合槐耳颗粒的疗效及对部分标志因子的影响[J].西部医学,2019,31(1):113-117.

更新日期/Last Update: 1900-01-01